Pages that link to "Q50448714"
Jump to navigation
Jump to search
The following pages link to Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension (Q50448714):
Displaying 50 items.
- Options for empagliflozin in combination therapy in type 2 diabetes mellitus (Q26745771) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (Q27301948) (← links)
- Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects (Q28072765) (← links)
- Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure (Q28080114) (← links)
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials (Q30248634) (← links)
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus (Q30249371) (← links)
- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials (Q31112303) (← links)
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis (Q32186373) (← links)
- Therapeutic Differences in 24-h Ambulatory Blood Pressures in Patients Switched Between Bioequivalent Nifedipine Osmotic Systems With Differing Delivery Technologies (Q33648055) (← links)
- Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus (Q33871321) (← links)
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. (Q33890770) (← links)
- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study (Q35117192) (← links)
- SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials (Q35181821) (← links)
- Short commentary on empagliflozin and its potential clinical impact (Q35528797) (← links)
- The role of empagliflozin in the management of type 2 diabetes by patient profile (Q35592873) (← links)
- Aspects of Hyperglycemia Contribution to Arterial Stiffness and Cardiovascular Complications in Patients With Type 1 Diabetes (Q35950003) (← links)
- Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin (Q36303346) (← links)
- Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes (Q36341246) (← links)
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial (Q36402095) (← links)
- The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus (Q36592820) (← links)
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus (Q36622125) (← links)
- Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs (Q36638899) (← links)
- Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes (Q36926197) (← links)
- A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes (Q36960633) (← links)
- Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. (Q37097189) (← links)
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option (Q37308941) (← links)
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (Q37325818) (← links)
- Blood pressure control in type 2 diabetic patients (Q37566950) (← links)
- Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes (Q37586729) (← links)
- Novel approaches for treating hypertension (Q37620461) (← links)
- The renal effects of SGLT2 inhibitors and a mini-review of the literature (Q37632127) (← links)
- Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study (Q37721942) (← links)
- Empagliflozin: a review of its use in patients with type 2 diabetes mellitus (Q38255999) (← links)
- Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials (Q38353558) (← links)
- Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence (Q38364908) (← links)
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (Q38389823) (← links)
- Extra-glycaemic properties of empagliflozin. (Q38494441) (← links)
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans (Q38537119) (← links)
- The effect of SGLT2 inhibitors on cardiovascular events and renal function. (Q38614488) (← links)
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment (Q38619164) (← links)
- Dapagliflozin combination therapy in type 2 diabetes mellitus (Q38634051) (← links)
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials (Q38654762) (← links)
- The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease (Q38679997) (← links)
- Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. (Q38762808) (← links)
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis (Q38776029) (← links)
- Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes (Q38783203) (← links)
- Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus (Q38796262) (← links)
- Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development (Q38806457) (← links)
- Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician (Q38821464) (← links)